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1. Introduction 
The type 1 diabetes mellitus (formerly known as insulin-dependent diabetes mellitus) is a 
chronic autoimmune disorder that precipitates in genetically susceptible individuals by 
environmental factors (Atkinson and Eisenbarth 2001). The body’s own immune system 
attacks the beta-cells in the islets of Langerhans of the pancreas, destroying or damaging 
them sufficiently to reduce and eventually eliminate insulin production. 
The increase in understanding of the pathogenesis of type 1 diabetes has made it possible to 
consider intervention to slow the autoimmune disease process in an attempt to delay or 
even prevent the onset of hyperglycemia but varying in terms of their genetic, 
environmental, and amphopometric measures (2003).  
Can we really predict type 1 diabetes? This is question has been a major target of diabetes 
research over the last decade. The aims have been to find a way of identifying individuals at 
risk and to accurately define their degrees of risk. Subjects who are at high risk for type 1 
diabetes (T1D) can be identified using a combination of immune, genetic, and metabolic 
markers, For example, prediction of T1D among relatives can be quite accurate, by 
combining screening of relatives by measurement of islet cell autoantibodies with 
subsequent assessment of insulin autoantibodies (IAAs), first-phase insulin response to 
intravenous glucose, and oral glucose tolerance, while excluding those relatives with the 
known protective genetic allele HLA-DQB1-0602 (Pugliese, Gianani et al. 1995). 
Using this combination approach and screening approximately 100,000 relatives, it was 
possible to identify accurately two cohorts of relatives, one (339 individuals) with a 
projected 5-year risk of greater than 50% and actual 5-year risk of 60%, (2002) and another 
(372 individuals) with a projected 5-year risk of 25–50% and actual 5-year risk of 35% 
(Skyler, Krischer et al. 2005). 
The seminal research discovery of islet cell cytoplasmic autoantibodies (ICA) in 1974 not 
only offered clues to the autoimmune basis for type 1 diabetes but in addition, aided in 
providing some degree of clarity to the aforementioned difficulties associated with disease 
classification and diagnosis (Bottazzo, Florin-Christensen et al. 1974). The discovery of 
autoantibodies in T1D also supported the formation of a series of studies defining the 
natural history of metabolic and immunologic events underling the formation of this 
disease, the biochemical nature of islet cell autoantigens in the disorder, and trials 
attempting to predict as well as prevent the formation of T1D. 
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2. Animal models of type 1 diabetes  
The availability of two animal models of type 1 diabetes has made it possible to evaluate 
plausible therapeutic strategies before starting human trials. Non-obese diabetic (NOD) 
mice and BioBreeding (BB) rats are in-bred strains that spontaneously develop autoimmune 
insulitis and diabetes with striking similarities to type 1 diabetes in humans (Mordes, 
Desemone et al. 1987; Elias and Cohen 1994).  
The present landscape of basic and translational research in animal models of T1D is 
characterized by overuse of the NOD mouse. This scenario has some historic reasons that 
are understandable, foremost among those being the fact that NOD mice and humans share 
several susceptibility-related genes, including genes encoding the MHC class II homologs. 
But it is now also known that there is considerable complexity and heterogeneity in both the 
disease and in the genetics of the disease, and a singular focus on the NOD model generates 
too narrow a perspective. 
The cumulative incidence of type 1 diabetes in these animals is high, and the onset of 
insulitis as well as hyperglycemia can be readily detected. Several interventions have been 
tested in these animals, often at a very early stage in the autoimmune disease process before 
the onset of insulitis. Examples include subcutaneous and oral insulin, nicotinamide, and 
the ß-cell antigen glutamic acid decarboxylase. Of note, many interventions have been 
effective in the murine models when applied before the development of hyperglycemia; 
however, very few interventions have reversed established diabetes. 
3. Natural history of preclinical type 1 diabetes in humans 
Type 1 diabetes is usually caused by autoimmune destruction of the insulin-producing ß-
cells in the islets of Langerhans (Atkinson and Maclaren 1994). In the new classification of 
diabetes, immune mediated type 1 diabetes is called type 1A to distinguish it from some 
rarer cases in which an autoimmune etiology cannot be determined (type 1B); the latter are 
said to be idiopathic (1997).  
Type 1 diabetes (T1D) occurs in genetically susceptible subjects. However many agree that 
an individual's genetic predisposition to this disease modified by environmental factors 
likely form a key facet for development (Knip 2003) (figure 1).  
Indeed, the genetic predisposition for T1D, like most autoimmune disorders, in large part 
resides within genes controlling the immune response, principal amongst these being the 
major histocompatiblity complex (MHC). However, susceptibility and resistance for T1D 
does not reside in the MHC alone as more than two dozen additional loci outside of the 
MHC complex have been identified to influence risk for this disease (Melanitou, Fain et al. 
2003; Atkinson 2005). Among the many potential candidate genes residing in such loci are 
BCL2, CD28, CTLA-4, CXCL12, interleukin-2 receptor and INS genes (Atkinson 2005). 
The potential influence of environmental factors in T1D development has been suggested 
through multiple observations, the primary ones being the 500-fold variance in disease 
incidence based on geographic locale, seasonal variance in disease onset, and somewhat 
dramatic increases in the frequency of this disease, particularly over the last half-century. 
While environmental factors influencing T1D development have remained elusive (i.e., none 
have specifically been isolated), epidemiological studies have associated infant diet, viruses 
and perhaps increased hygiene as contributing events to this disease (Knip 2003). In terms of 
how they might contribute to disease, without specific identification, such models remain 
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Fig. 1. The natural history of type 1 diabetes is depicted. In individuals with genetic 
predisposition to beta-cell autoimmunity, exposure to an environmental trigger or triggers is 
believed to initiate beta-cell autoimmunity, first evidenced in the appearance of islet 
autoantibodies. If beta-cell necrosis ensues as a consequence of destructive betacell cellular 
autoimmunity, a subclinical reduction in beta-cell mass ensues. The first clinical evidence of 
beta-cell dysfunction is an abnormal IVGTT result. With continued damage to the beta-cells, 
the OGTT will become abnormal. Within 1–2 years, frank symptoms of type 1 diabetes 
usually evolve (Winter, Harris et al. 2002). 
hypothetical, but it is currently speculated that once the pathway to T1D has been initiated, 
either through as yet unknown triggers or natural physiological processes, various aberrant 
immune responses begin to play a role. It is important to note that many theories for 
environmental contributions to T1D development (e.g., viral molecular mimicry, ǃ-cell 
trophic viruses, cow milk consumption, childhood vaccines, etc.), while popular in terms of 
their notion, have not proven themselves reproducible across a variety of study populations 
over time (Litherland, Xie et al. 1999; Atkinson 2005). 
Despite genetics and environment forming knowledge voids for T1D pathogenesis, models 
for T1D development have been proposed that include these factors in combination with 
other findings (e.g., immunoregulatory defects, rate of metabolic loss, formation of anti-islet 
antibodies, etc.) which have been subject to better and more detailed description 
(Litherland, Xie et al. 1999). Under one such natural history model, defects in antigen 
presentation as well as antigen presenting cell maturation imparts an unnatural arrest in 
clearance of immune cells from the islets. The additional inability to regulate this response 
to self-antigens, a facet largely controlled by genetic susceptibility, would ultimately lead to 
a destructive islet cell inflammation (i.e., insulitis), with death of the insulin secreting ǃ-cells 
(Brusko, Wasserfall et al. 2005). As the total ǃ-cell mass declines, a critical point is reached 
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where glucose homeostasis is lost and eventually exogenous insulin is an absolute 
requirement for survival. 
Aside from model systems, thoughts continue that T-lymphocytes play the predominant 
role either directly (cytotoxicity) or indirectly (cytokine mediated ǃ-cell apoptosis) in the 
destruction of islets. Adoptive transfer experiments in animal models have shown that T-
lymphocytes transfer disease and serum does not. At the same time, recent studies have 
suggested key roles for B-lymphocytes in this process as one mouse model for T1D, the 
NOD mouse, when rendered deficient in these cells (either through genetic manipulation or 
through antibody treatment) fail to develop overt disease. 
Hence, at one level, it is clear that B-lymphocytes are also involved inasmuch as they do 
produce autoantibodies (Brusko, Wasserfall et al. 2005) and in reality, it has been 
hypothesized that antigens presented by B lymphocytes may represent a critical feature to 
the development of T1D. 
However, several aspects of the natural history of preclinical type 1 diabetes remain unclear, 
including the rate of progression and the changes in and predictive value of genetic and 
metabolic markers. 
4. Biomarkers of susceptibility - tools for disease prediction 
4.1 Genetic markers 
Genetic markers may be helpful in assessing the risk of type 1 diabetes in close relatives of a 
patient with type 1 diabetes. The risk is markedly increased in these relatives, averaging 
about 6 percent in offspring and 5 percent in siblings (versus 0.4 percent in subjects with no 
family history) (Atkinson and Maclaren 1994). 
The major genetic determinants of type 1 diabetes reside in the HLA region within the major 
histocompatibility complex (MHC) on the short arm of chromosome 6. An association 
between HLA class I alleles and type 1 diabetes was first described in the early 1970s 
(Nerup, Platz et al. 1974). More recent observations have indicated that the genes in the 
HLA-DQ region are even more closely associated with type 1 diabetes than the DR genes 
(Morel, Dorman et al. 1988). Over 90 percent of patients with type 1 diabetes carry DR4, 
DQB*0302 and/or DR3, DQB*0201. Thus, if the proband is heterozygous for DR3 and DR4 
(the highest risk combination), the incidence of type 1 diabetes in a sibling who shares these 
two haplotypes rises to 19 percent. On the other hand, the absence of the above alleles 
makes type 1 diabetes very unlikely, especially if the subject carries a protective allele such 
as DQB*0301, *0602 (Pugliese, Gianani et al. 1995), DRB*0403, or *0406. 
Use of genetic markers plus the family history make it possible to estimate the risk of type 1 
diabetes as being as low as one in 5000 (no susceptibility alleles or family history) to as high as 
one in four (two susceptibility alleles and a positive family history). However, the prevalence 
of the HLA susceptibility genes is relatively high in whites. As a result, the predictive value of 
HLA typing is much lower in population screening than it is among families in which one or 
more members have type 1 diabetes (Bingley, Bonifacio et al. 1993) (Table 1). 
In one study, the risk for islet autoimmunity drastically increased in DR3/4-DQ2/DQ8 
siblings who shared both HLA hapl9otypes identical by descent with their diabetic proband 
sibling (63 and 85 percent by ages 7 and 15, respectively) as compared to siblings who did 
not share both HLA haplotypes with their diabetic proband sibling (Aly, Ide et al. 2006). 
These data suggest that HLA genotyping at birth may identify individuals at very high risk 
of developing type 1 diabetes before the occurrence of clear signs of islet autoimmunity and 
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type 1 diabetes onset. Rapid automated assays make it possible to do large-scale population 
screening for HLA easily, even in newborns  (Ilonen, Reijonen et al. 1996; Rewers, Bugawan 
et al. 1996) 
 
 
Table 1. Type 1 Diabetes Risk Stratification by T1D Family History and HLA Genotyping. 
In general, the additional measurement of 2 HLA-DQ high-risk haplotypes does not increase 
the predictive value of combined autoantibody assays. However, in relatives who are 
seronegative for conventional islet autoantibodies, the presence of two HLA-DQ high-risk 
haplotypes is associated with an increased risk of progression to type 1 diabetes (Pietropaolo, 
Becker et al. 2002). This observation suggests that unidentified autoimmune phenomena may 
be present in seronegative relatives who carry the 2 HLA-DQ high-risk haplotypes. 
Furthermore, specific allelic combinations of variants in the insulin gene (INS), the cytotoxic 
T lymphocyte antigen-4 gene (CTLA4) and the protein tyrosine phosphatase, non-receptor 
type 22 gene (PTPN22) have been repeatedly associated with type 1 diabetes susceptibility 
(Undlien, Lie et al. 2001; Pugliese and Miceli 2002; Ueda, Howson et al. 2003) using different 
approaches and increasing the number of susceptibility loci considered simultaneously 
generally increases the predictive value for T1D disease. The receiver operating 
characteristic (ROC) curve analysis confirms that, despite the higher absolute risk for those 
few with combinations of several risk markers, adding non-HLA genetic markers only 
marginally increases the utility of the prediction over that of HLA alone. 
Despite near-multiplicative effects for most loci, and the fact that groups with very high 
relative risk of type 1 diabetes can be identified by testing for multiple susceptibility genes, 
only a small proportion of the population (and cases with type 1 diabetes) simultaneously 
carry HLA and multiple non-HLA susceptibility genotypes. 
4.2 Immunologic markers 
4.2.1 Islet autoantibodies:  
The most important change in the T1D risk status of a child occurs when islet autoantibodies 
develop. Several clinically useful serum autoantibodies can be detected during the 
preclinical period of type 1 diabetes, including islet-cell antibodies (ICA), insulin 
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autoantibodies (IAA), antibodies to glutamic acid decarboxylase (GAD), and antibodies to 
tyrosine phosphatase-like proteins such as insulinoma associated protein (IA-2, ICA512).  
Furthermore, only 8 to 10% of all cases of type 1 diabetes have a family history, while 90% of 
cases occur sporadically (Dahlquist, Blom et al. 1985). It was therefore important to examine 
the prevalence and the prognostic value of autoantibodies in the general population. 
ICA is polyclonal autoantibodies that react with all cells of the islet (i.e., ǂ, ǃ, δ, and 
pancreatic polypeptide cells). The next major discovery in terms of humoral autoimmunity 
in T1D was that of autoantibodies to insulin or IAA (Williams, Bingley et al. 1999). 
The presence of ICA was associated with an increased risk of diabetes, particularly if the 
ICA titer was high, ICA were persistently detected, or ICA were present in combination 
with IAA or GAD antibodies (Verge, Stenger et al. 1998). 
Similar findings have been reported with IA-2. In one study of first-degree relatives of type 
1 diabetic probands, those with IA-2 autoantibodies in the upper three quartiles were at 
higher risk than relatives with an IA-2 autoantibody titer in the lowest quartile (Achenbach, 
Bonifacio et al. 2008). 
In another study, an autoantibody response directed to the extracellular domain of IA-2 was 
associated with very high risk of type 1 diabetes progression, suggesting the presence of 
new antigenic determinants within the extracellular domain of IA-2 (Morran, Casu et al.). 
This has considerable implications not only for stratifying high type 1 diabetes risk, but also 
to facilitate the search for pathogenic epitopes to enable the design of peptide-based 
immunotherapies, which may prevent the progression to overt type 1 diabetes at its 
preclinical stages. 
Unlike NOD mice, an animal model for type 1 diabetes, humans exhibit any combination of 
ICA, IAA, GAD, and IA-2 antibodies (Kaufman, Clare-Salzler et al. 1993; Tisch, Yang et al. 
1993; Greenbaum, Sears et al. 1999). The risk of type 1 diabetes is relatively low with IAA 
alone, but is higher with the presence of multiple autoantibodies against islet antigens 
(insulin, GAD, IA-2 and ICA) (Bingley 1996; Pietropaolo and Eisenbarth 2001). Antibodies to 
GAD are predictive of progression to hyperglycemia even in the absence of ICA or IAA 
(Verge, Stenger et al. 1998). As with IAA, however, the risk is higher in subjects who are 
ICA-positive. 
Parallel studies have shown the presence of these autoantibodies in the sera of individuals 
prior to the onset of T1D (Bingley 1996; Bingley, Bonifacio et al. 2001; Achenbach, Warncke 
et al. 2004). At the onset of disease using GADA, IA–2A and IAA in combination offers 
N85% sensitivity and 98% specificity (Bingley, Bonifacio et al. 2001). The sensitivity at onset 
of T1D for ICA is 70–90%, GADA 70–80%, IA–2A 50–70% and IAA 30–50% respectively, 
with the variances in the ranges reflecting the population differences between studies. In 
terms of prediction, multiple large intervention trials, while failing to prevent T1D, have 
validated the predictive value of these autoantibodies for T1D (Gale, Bingley et al. 2004) 
(Figure 2). 
The titter of IAA has been used to predict the time to onset of type 1 diabetes, particularly in 
children younger than five years of age (Ziegler, Ziegler et al. 1989). In a prospective, cohort 
study of 1353 offspring of parents with type 1 diabetes, antibodies detected in the first six 
months were derived by placental transfer from the mother. Autoantibodies began to 
appear by nine months and frequently persisted. IAA were almost always the first to 
appear, with other antibodies (ICA, GAD, or IA-2) appearing later. By age five years, nine 
(1.8 percent) children had developed type 1 diabetes, and all had one or more 
autoantibodies beforehand. Fifty percent of children who had two or more antibodies 
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Fig. 2. Type 1 diabetes (T1D) risk stratification by islet autoantibody characteristics. 
Characteristics associated with low, intermediate, high, and very high risk are grouped from 
left to right on the abscissa with corresponding T1D risks on the ordinate. Increase in T1D 
risk is associated with progression of islet autoantibodies from single to multiple 
autoantibodies. HLA genotype discriminates risk in single antibody–positive children, but 
multiple antibody–positive children have high risk regardless of HLA genotype. 
present by two years had diabetes by age five years (Ziegler, Hummel et al. 1999). In a 
follow-up report of a slightly larger cohort (1610 offspring), the following results were seen 
(Hummel, Bonifacio et al. 2004): 
 By age five years, the frequencies of islet autoantibodies, multiple autoantibodies, and 
type 1 diabetes were 5.9, 3.5, and 1.5 percent, respectively. 
 The risk of diabetes was highest in those with multiple autoantibodies (40 percent 
within five years versus 3 percent in those with single autoantibodies). 
 Progression to multiple islet autoantibodies was fastest in children who developed their 
first autoantibody by age two years. 
 The risk of progression to diabetes was inversely related to the age of positivity for 
multiple islet autoantibodies (50 percent of children who had multiple positivity before 
age 9 months developed diabetes within two years, compared to 7 percent in those who 
had multiple autoantibodies at age five years). 
Thus, children with the earliest evidence of autoimmunity are at greatest risk for and 
progress more quickly to the development of type 1 diabetes. Periodic testing for islet 
autoantibodies appears to help assess the risk of diabetes in children of parents with type 1 
diabetes. 
In another study of 81 Swedish children who later developed type 1 diabetes, 14 (17 percent) 
had at least one autoantibody present at birth (either GAD, IAA, or ICA512), as compared 
with 12 of 320 (4 percent) control children (Lindberg, Ivarsson et al. 1999). Four percent had 
www.intechopen.com
 
Type 1 Diabetes – Pathogenesis, Genetics and Immunotherapy 638 
more than one autoantibody present, compared with none of the control children. This 
study suggests that the autoimmune process may start in utero, but that this is rare. 
In addition to identifying subjects at risk for type 1 diabetes, the presence of ICA and GAD 
antibodies can also identify late-onset type 1 diabetes in adults thought to have type 2 
diabetes. In a study of 97 Swedish diabetic patients who were initially thought to have type 
2 or unclassifiable diabetes, 70 became insulin-dependent after six years of follow-up. 
Among these 70 patients, 60 percent were positive for either ICA or GAD at diagnosis, 
compared with only 2 percent of the 27 patients who remained responsive to oral therapy. 
The presence of these serological markers was closely correlated with histological evidence 
of insulitis in a study of 29 patients with recently diagnosed type 1 diabetes (Imagawa, 
Hanafusa et al. 2001). Pancreatic biopsies obtained within these months of diagnosis 
revealed a T-cell infiltration of pancreatic islets and hyperexpression of HLA class I antigens 
on islet cells. These features were much more evident among patients with high serum ICA 
concentration, or the presence of GAD, IAA, or multiple antibodies. 
The absence of islet autoantibodies, however, does not exclude type 1 diabetes (House and 
Winter 1997). The appearance of islet autoantibodies in pancreas transplant recipients 
predicts recurrence of type 1 diabetes (Bosi, Braghi et al. 2001). Type 1 diabetes can occur 
after organ donation, and thus living kidney donors from families with histories of type 1 
diabetes should be screened for islet autoantibodies (Riley, Maclaren et al. 1990). 
4.2.2 Zinc transporter antibodies 
In 2007, zinc transporter-8 (ZnT8) was identified as a novel diabetes autoantigen (Wenzlau, 
Juhl et al. 2007).  Autoantibodies against the cation efflux zinc transporter (ZnT8A) have also 
been identified as a candidate type 1 diabetes autoantigen and proposed as additional 
markers of rapid disease progression (Wenzlau, Juhl et al. 2007). This study demonstrated 
that ZnT8 antibodies (ZnTA) were found in 26% of T1D subjects classified as autoantibody-
negative on the basis of existing markers (GADA, IA2A, IAA, and ICA). In addition, sixty to 
80 percent of patients with newly diagnosed type 1 diabetes have ZnT8 autoantibodies.  
The function of this transporter is unknown. But, the combined measurement of ZnT8A, 
GADA, IA2A, and IAA raised autoimmunity detection rates to 98% at disease onset, a level 
that approaches that needed to detect prediabetes in a general pediatric population. 
A recent study was examined the added value of measuring both IA-2ǃA and ZnT8A for 
prediction of impending diabetes in siblings or offspring of type 1 diabetic patients. It 
confirms the association of IA-2A, IA-2ǃA and ZnT8A with rapid disease progression and 
demonstrates that IA-2A and ZnT8A represent the most sensitive combination of two 
markers to identify relatives with a high progression rate. 
4.3 Metabolic markers 
Efficacious prevention of T1D will require detection of the earliest events in the process. 
Autoimmunity is likely the predominant effector mechanism in T1D, but it is possibly not its 
primary cause. A recent interesting report by Oresic et al. (Oresic, Simell et al. 2008) (see 
sect. VA) showed that elevated serum concentrations of lysophosphatidyl choline precede 
the appearance of each islet autoantibody, and thus overt autoimmunity, in T1D. If these 
results are validated in other well-characterized cohorts, like the German BABYDIAB 
(Achenbach, Koczwara et al. 2004; Baschal, Aly et al. 2007), the United States-based DAISY 
(Baschal, Aly et al. 2007) and PANDA (Carmichael, Johnson et al. 2003) studies, and the 
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multinational TEDDY study (Hagopian, Lernmark et al. 2006), metabolome screening could 
be added to the screening panel to effectively identify pre-diabetic  individuals for 
preventive treatments. 
Although glucose tolerance remains normal until close to the onset of hyperglycemia 
(Atkinson, Maclaren et al. 1990), the acute insulin response to several secretagogues 
(glucose, arginine, glucagon and isoproterenol) decreases progressively during the 
preclinical period (Aanstoot, Sigurdsson et al. 1994). The most useful and widely performed 
test is the acute (or "first phase") insulin response to glucose (FPIR) during an intravenous 
glucose tolerance test (IVGTT); in this test the rise in serum insulin above baseline is 
measured during the first 10 minutes after an intravenous glucose challenge; the response 
correlates with the functioning ß-cell mass (figure 3). The IVGTT has been standardized to 
allow easier comparison between centers (McCulloch, Bingley et al. 1993). In first-degree 
relatives of patients with type 1 diabetes, for example, an FPIR below the first percentile of 
normal is a strong predictor of type 1 diabetes. 
In the Diabetes Prevention Trial-Type 1 Diabetes (DPT-1), subjects at high risk for 
developing diabetes were followed with serial IVGTTs and oral glucose tolerance tests 
(OGTTs), and in a subsequent study, the metabolic factors associated with progression to 
diabetes were evaluated (Barker, McFann et al. 2007). 
 
 
Fig. 3. Relative acute insulin response to IV glucose. Reproduced with permission from 
Brunzell et al. (Brunzell, Robertson et al. 1976) http://jcem.endojournals.org. Copyright © 
1976 The Endocrine Society. 
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Abnormalities of FPIR and two-hour glucose during OGTT had similar sensitivities for 
diabetes prediction within six months of diagnosis (76 percent for OGTT [95% CI 60-83%] 
and 73 percent for FPIR [95% CI 60-83%]). Sensitivity was better when both tests were 
performed, and the vast majority of these individuals (97 percent) had abnormal IVGTTs 
and/or OGTTs before the development of the overt diabetes. In contrast, fasting blood 
glucose levels were a poor predictor of diabetes. 
The more important as pathogenetical significance was the finding of increased proinsulin 
in first degree relatives or descendants from diabetic parents, both with type 1 (Roder, Knip 
et al. 1994; Truyen, De Pauw et al. 2005). Truyen et al. (Truyen, De Pauw et al. 2005) 
considered that the increased plasma proinsulin levels can be an additional marker for the 
prediction of type 1 diabetes.  A simpler test that may prove useful is to measure the fasting 
serum concentration of proinsulin, the precursor of insulin. In normal subjects, proinsulin 
accounts for approximately 15 percent of serum immunoreactive insulin. This proportion 
rises as ß-cell function declines. One report, as an example, found that serum proinsulin 
concentrations were three to four times higher among ICA-positive relatives of type 1 
diabetes patients as compared with ICA-negative relatives. However, prospective studies 
are needed to determine whether elevated serum proinsulin values will help in predicting 
the development of type 1 diabetes. 
4.4 Combining risk biomarkers 
Since genetic susceptibility is only part of the risk factors for common diseases, genetic 
markers alone usually do not have adequate specificity. There is growing evidence that 
combining multiple genetic and clinical markers is the best way to develop a molecular test 
with clinically useful predictive power. 
Various combinations can be used to obtain similar overall risk, and for most combinations 
the risk can be calculated empirically. Risk can be stratified from less than 0.1% to greater 
than 70%. Current approaches use a stepwise decision tree (Krischer, Cuthbertson et al. 
2003) in which genetic risk is usually the first applied in the form of family history or HLA 
DR-DQ genotype. Autoantibodies are measured in those individuals who are considered to 
have sufficient genetic risk to warrant autoantibody testing. Because the risk of developing 
multiple islet autoantibodies is strongly linked to major histocompatibility complex (MHC) 
class II genotypes,(Walter, Albert et al. 2003) further typing is unlikely to be helpful in a 
child who has an armada of islet autoantibodies. Finally, beta cell function is measured in 
islet autoantibody–positive individuals using either the ability of the beta cell to secrete 
insulin in response to an intravenous glucose challenge or the ability of the individual to 
clear glucose after a meal challenge where low insulin secretion (eg, less than the first 
percentile) or impaired glucose tolerance are indicators of late-stage preclinical T1D. 
Although the decision tree approach is logical, it may be expected that once effective 
preventative therapies become available, the decision tree approach could be replaced by 
the population-wide application of all the previously mentioned markers in a public health 
prevention manner. Clinicians may eventually move toward introducing a risk score based 
on the combination of all markers. This would represent a paradigm shift after years of 
increasingly complex layers of decisions in screening. 
Finally, the T1D risk of an individual is not static throughout life. This is true even for 
genetically defined risk. Risk in a child who has no family history of T1D at birth increases 
more than 10-fold if his or her sibling develops T1D, and if the child has an identical twin 
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who develops T1D, risk immediately increases 100-fold to around 50% (Redondo, Jeffrey et 
al. 2008). Risk calculated from the autoantibody status usually increases over time as 
autoantibodies appear and their number rises. Younger age is associated with increased risk 
than older age. Beta cell function measures are expected to show decrease the closer 
someone is to disease onset. Over the lifespan of an individual, the calculated T1D risk on 
the basis of genes, autoantibody, age, and beta cell function change. 
5. Conclusions 
Type 1 diabetes is an immunemediated disease leading to chronic insulin deficiency due to 
extensive and selective -cell destruction in subjects with increased genetic disease 
susceptibility  (Atkinson and Eisenbarth 2001). As far as diagnosis of T1D versus other 
forms of diabetes the autoantibodies and genetic markers are of great value. There remains a 
subset of patients that are autoantibody negative at onset. This subset may at times present a 
diagnostic challenge and it is of importance for treatment to know if T1D (absolute 
requirement for insulin) or type 2 diabetes with a relative insulin resistance is present. 
The occurrence of multiple antibodies against islet autoantigens serves as a surrogate 
marker of disease in primary or secondary intervention strategies aimed at halting the 
disease process (Pietropaolo and Eisenbarth 2001). Genetic typing for susceptibility or 
protective HLA alleles can also be performed. 
In a research setting, the following approach may be used (McCulloch and Palmer 1991): 
 Test individuals at risk for type 1 diabetes progression for GAD65 and IA-2 
autoantibodies. 
 If they are present and confirmed in a subsequent sample, tests for insulin and islet cell 
antibodies can be done and the FPIR determined. 
Nonetheless, the studies performed to date have given us tremendous insight into the 
natural history of T1Ds (Eisenbarth 2004; Achenbach, Bonifacio et al. 2005; Sherry, Tsai et al. 
2005). As a consequence, at present we can predict the development of T1D. Ideally, we 
would like to couple such prediction with prevention, but unfortunately we do not yet have 
a safe and effective preventive therapy. 
Successful prevention depends on 1) a good prediction/ identification of at-risk individuals 
and 2) a very safe intervention that causes no harm in those individuals who would have 
never developed T1D. Knowledge of the primary cause of T1D might not be crucial, even at 
the preventive stage. This statement is based on the fact that immune modulation appears to 
work in a variety of T1D models and at different stages of the disease. However, many 
preventive trials are based on data from the NOD mouse model which has improved our 
understanding of disease pathophysiology. A comprehensive analysis by Shoda et al. 
(Shoda, Young et al. 2005) concluded that “some popular tenets regarding NOD 
interventions were not confirmed: all treatments do not prevent disease, treatment dose and 
timing strongly influence efficacy, and several therapies have successfully treated overtly 
diabetic mice.” So, the good news is that some preventive strategies appear to have a good 
chance to cure the disease, even during an advanced status of beta-cell destruction. Examples 
of succesful treatments in NOD mice are ATG, anti-CD3, hsp, and proinsulin DNA vaccine. 
 Ideally, the balance between therapeutic efficacy and disease stage should be known prior 
to human trials. 
A major problem with preventive trials is that it takes many years before conclusions can be 
drawn. As can be seen in Table 2, preventive trials divide in two main classes.  
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Table 2. Prevention trials in T1D. 
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